IN8bio, Inc. (INAB) vs Karyopharm Therapeutics Inc. (KPTI)
A side-by-side comparison of IN8bio, Inc. and Karyopharm Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INAB
IN8bio, Inc.
$1.41HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
KPTI
Karyopharm Therapeutics Inc.
$0.64HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
Total return — INAB vs KPTI
growth of $100 · dividends reinvested · last 5yINAB -99.5% (-65.7%/yr)KPTI -99.5% (-64.9%/yr)KPTI compounded faster over this window
INAB KPTI
INAB vs KPTI: by the numbers
- •KPTI is the larger company ($14M vs $13M market cap).
- •Both run net losses; INAB's is the smaller (0.00% vs -153.28% net margin).
Metrics side by side
Valuation
| Metric | INAB | KPTI |
|---|---|---|
| P/S ratio | N/A | 0.10 |
| P/B ratio | 0.73 | N/A |
Profitability
| Metric | INAB | KPTI |
|---|---|---|
| Gross margin | 0.00% | 95.88% |
| Operating margin | 0.00% | -56.17% |
| Net margin | 0.00% | -153.28% |
| ROE | -101.66% | N/A |
| ROIC | -91.74% | N/A |
Growth (annualized)
| Metric | INAB | KPTI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.47% |
| Total return CAGR (5Y) | -62.88% | -62.18% |
Frequently asked
- How have INAB and KPTI total returns compared?
- Over the past 5 years, INAB delivered -62.88% and KPTI delivered -62.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.